BIOTRONIK SE & Co.KG's Launch of AlCath®Flutter Gold Advances the Treatment of Atrial Flutter With High-End Stability in Clinical Practice
9/19/2013 11:33:17 AM
BERLIN, Germany, September 19, 2013—BIOTRONIK announced the European market launch of its AlCath Flutter Gold ablation catheter today. Prof. Thorsten Lewalter, MD, Director of the Isar Heart Center Munich, Medical Center for Cardiology and Internal Intensive Care, successfully performed the first AlCath Flutter case worldwide as part of an international product evaluation, which was successfully completed in 16 centers across Europe and Israel. Physicians rated the stability of AlCath Flutter Gold in various anatomical positions as excellent compared to their standard catheter of choice.
AlCath Flutter Gold is the latest from BIOTRONIK in the electrophysiology sector and the result of 10 years of experience in this field. BIOTRONIK pioneered GoldTip ablation in 2003 and at the time was the first and only company to advance this type of ablation technology. In developing the AlCath Flutter Gold, BIOTRONIK focused on refined control and superior stability while maintaining the core features of previous successful catheter generations.
The new catheter guarantees the highest amount of control in order to follow isthmus anatomy smoothly without jumping off or losing effective contact. Using innovative technology such as high density braiding and lateral stabilization of the tip segment, AlCath Flutter Gold applies contact force more effectively than currently available products.
According to Professor Lewalter, an internationally renowned leader for the treatment of arrhythmia and ablation therapy, the first use of the new AlCath Flutter Gold to treat atrial flutter was an overwhelming success.
“The superior control offered by this new ablation catheter provides me with greater precision,” said Prof. Lewalter. “While BIOTRONIK’s AlCath Gold series has always offered efficiency and safety in various tachycardia treatments, the advanced stability of this new catheter makes it optimal for treating atrial flutter. Now I can ablate with effective contact force, even in the most challenging target sites of the tricuspid isthmus anatomy.”
“BIOTRONIK has been a pioneer in GoldTip ablation therapy, perfecting the technology over the last 10 years,” explained Christoph Böhmer, President International at BIOTRONIK. “Now BIOTRONIK once again does what it has always done best: listen to what EP experts had to say about the challenging aspects of daily clinical practice to create a product that benefits both physician and patient. AlCath Flutter Gold is an important new addition to our electrophysiology portfolio, demonstrating BIOTRONIK’s continued commitment to serving our customers in the rapidly growing field of ablation therapy.”
About BIOTRONIK SE & Co. KG
As one of the world’s leading manufacturers of cardiovascular medical devices, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries by its global workforce of more than 5,600 employees. Several million heart patients around the world have received BIOTRONIK implants, designed to save and improve the quality of their lives. Since its development of the first German pacemaker in 1963, BIOTRONIK has launched several innovations into the market—including remote monitoring with BIOTRONIK Home Monitoring® in 2000 and the world’s first implantable cardioverter-defibrillators and implantable heart failure therapy devices with ProMRI® technology, approved for MR scanning, in 2012. This year BIOTRONIK is celebrating its 50th anniversary.
For more information, visit: www.biotronik.com
Global Communications Manager
BIOTRONIK SE & Co. KG
Tel. +49 (0) 30 68905 1466
Help employers find you! Check out all the jobs and post your resume.
comments powered by